Cytokinetics' comeback attempt with second-gen drug is slammed by a PhII failure in ALS

Seventeen months after Cytokinetics’ lead muscle drug crashed and burned in a Phase III ALS trial, their $CYTK second-gen attempt has now gone down to defeat in a Phase II trial.